Viking Therapeutics (VKTX)

Going into JPM, the VKTX setup is being misunderstood because people keep debating it like a single-readout biotech instead of a program that’s already past most binary risk. The facts are simple. VK2735 is a dual GLP-1/GIP agonist with real Phase 2 efficacy signals in both injectable and oral formulations, and Viking has already moved into a full registrational footprint: two 78-week Phase 3 obesity trials, one fully enrolled at \~4,650 patients and the second in T2D at \~1,100. That’s not speculation, that’s execution. FDA has been clear across the class that approval is driven by long-duration weight loss, safety, and discontinuation, not event-driven outcomes like MACE or MASH, which are lifecycle programs run after approval at scale. That’s exactly how sema and tirz were built. What’s different here isn’t “magic biology” or buzzwords. It’s that Viking is explicitly studying what actually breaks obesity drugs in the real world: tolerability, drop-off, and how patients behave over time. That’s why there’s a dedicated maintenance regimen study testing cadence and exposure after induction. Most competitors don’t formally study that, even though everyone knows patients modulate doses or quit altogether. If VK2735 can deliver competitive 78-week WL with acceptable GI-driven discontinuation at doses people stay on, it can take share regardless of whether it’s numerically “best in class” at a single time point. Chronic markets are won on persistence, access, and supply, not headline curves. Near-term, JPM isn’t about surprise data. It’s about validation and positioning. The catalysts over the coming weeks are clarity around the oral path post-FDA interaction, tone around maintenance strategy, and any signal of BD interest now that enrollment is largely de-risked. Partnership is more plausible than outright M&A, but either would be incremental validation, not required for the thesis. Even absent a deal, confirming alignment on Phase 3 execution and the oral roadmap matters because uncertainty, not fundamentals, is what’s been priced. Bottom line: VKTX isn’t a lottery ticket and it isn’t hype-only. It’s a Phase 3 dual incretin with a real dataset coming and a credible commercial hypothesis focused on long-term use, not short-term optics. The debate doesn’t get settled on Reddit or Stocktwits. It gets settled when the 78-week data read out. Until then, this is a classic JPM setup where downside is known, upside is asymmetric, and time works for holders.